UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 2, 2017
Pacific Biosciences of California, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-34899 |
|
16-1590339 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
1305 O’Brien Drive
Menlo Park, California 94025
(Address of principal executive offices, including zip code)
(650) 521-8000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02.Results of Operations and Financial Condition.
On February 2, 2017, Pacific Biosciences of California, Inc. reported its financial results for its fourth fiscal quarter ended December 31, 2016. A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.
This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
ITEM 9.01. |
FINANCIAL STATEMENTS AND EXHIBITS. |
|||
|
|
|
|||
|
|
(d) |
Exhibits. |
||
|
|
|
|
|
|
||
|
|
|
|
|
99.1 |
|
Press Release dated February 2, 2017 titled “Pacific Biosciences Reports Fourth Quarter 2016 Financial Results” (furnished and not filed herewith solely pursuant to Item 2.02). |
|
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Pacific Biosciences of California, Inc. |
||
|
|
|
|
|
By: |
|
/s/ Susan K. Barnes |
|
|
|
Susan K. Barnes Executive Vice President, Chief Financial Officer & Principal Accounting Officer |
Date: February 2, 2017
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release dated February 2, 2017 titled “Pacific Biosciences Reports Fourth Quarter 2016 Financial Results” (furnished and not filed herewith solely pursuant to Item 2.02). |
Pacific Biosciences Announces Fourth Quarter 2016 Financial Results
Product and Service Revenue Increases by 92% Over Same Period in Previous Year
Menlo Park, Calif. – February 2, 2017 – Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter ended December 31, 2016.
Revenue for the fourth quarter of 2016 totaled $25.7 million, compared to $36.3 million for the fourth quarter of 2015. Product and service revenue for the fourth quarter of 2016 increased 92.2% to $24.4 million, compared to $12.7 million for the fourth quarter of 2015. Contractual revenue for the fourth quarter of 2016 was $1.3 million, reflecting the remaining $1.3 million of amortization of the upfront payment recognizable upon the termination of the Company’s development, commercialization and license agreement with F. Hoffman-La Roche Ltd in December 2016. Contractual revenue for the fourth quarter of 2015 was $23.6 million, reflecting $20.0 million of milestone revenue from Roche and $3.6 million of quarterly amortization of the upfront Roche payment.
Gross profit for the fourth quarter of 2016 was $11.4 million, resulting in a gross margin of 44.2%, compared to gross profit of $26.5 million and a gross margin of 72.9% for the fourth quarter of 2015. The gross profit and margin for the fourth quarter of 2015 was primarily driven by the $20.0 million revenue milestone from Roche, which had a 100% gross margin. Excluding this milestone revenue, gross profit and gross margin for the fourth quarter of 2016 increased significantly over the same period in 2015 primarily as a result of the higher margin sales of the Company’s SequelTM System which was launched in the fourth quarter of 2015.
Operating expenses totaled $29.3 million for the fourth quarter of 2016, compared to $27.5 million for the fourth quarter of 2015. Operating expenses for the fourth quarters of 2016 and 2015 included non-cash stock-based compensation of $4.3 million and $3.6 million, respectively.
The net loss for the fourth quarter of 2016 was $19.0 million, compared to a net loss of $1.4 million for the fourth quarter of 2015.
Cash, cash equivalents and investments, excluding restricted cash, at December 31, 2016 totaled $72.0 million, compared to $82.3 million at December 31, 2015.
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its fourth quarter 2016 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330,using an Audience Passcode of 6231-3559. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/ .
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development of products, future uses, quality or performance of, or benefits of using, products or technologies and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could
materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Contact:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(amounts in thousands, except per share amounts)
|
|
||||||||||||
|
|
Three-month Periods Ended |
Twelve-month Periods Ended |
||||||||||
|
|
December 31, |
December 31, |
||||||||||
|
|
2016 |
2015 |
2016 |
2015 |
||||||||
|
Revenue: |
||||||||||||
|
Product revenue |
$ |
20,593 |
$ |
9,799 |
$ |
64,609 |
$ |
37,502 | ||||
|
Service and other revenue |
3,783 | 2,886 | 13,971 | 10,896 | ||||||||
|
Contractual revenue |
1,346 | 23,596 | 12,134 | 44,384 | ||||||||
|
Total revenue |
25,722 | 36,281 | 90,714 | 92,782 | ||||||||
|
Cost of Revenue: |
||||||||||||
|
Cost of product revenue |
11,244 | 7,415 | 34,512 | 30,704 | ||||||||
|
Cost of service and other revenue |
3,104 | 2,400 | 12,042 | 8,628 | ||||||||
|
Total cost of revenue |
14,348 | 9,815 | 46,554 | 39,332 | ||||||||
|
Gross profit |
11,374 | 26,466 | 44,160 | 53,450 | ||||||||
|
Operating Expense: |
||||||||||||
|
Research and development |
16,255 | 14,752 | 67,617 | 60,440 | ||||||||
|
Sales, general and administrative |
12,993 | 12,776 | 47,787 | 45,187 | ||||||||
|
Gain on lease amendments |
— |
— |
— |
(23,043) | ||||||||
|
Total operating expense |
29,248 | 27,528 | 115,404 | 82,584 | ||||||||
|
Operating loss |
(17,874) | (1,062) | (71,244) | (29,134) | ||||||||
|
Interest expense |
(839) | (773) | (3,234) | (2,926) | ||||||||
|
Other income (expense), net |
(317) | 426 | 103 | 364 | ||||||||
|
Net loss |
$ |
(19,030) |
$ |
(1,409) |
$ |
(74,375) |
$ |
(31,696) | ||||
|
Basic and diluted net loss per share |
$ |
(0.21) |
$ |
(0.02) |
$ |
(0.83) |
$ |
(0.42) | ||||
|
Shares used in computing basic and diluted net loss per share |
92,660 | 78,327 | 89,148 | 75,614 | ||||||||
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(amounts in thousands)
|
|
|||||
|
|
December 31, |
December 31, |
|||
|
|
2016 |
2015 |
|||
|
Assets |
|||||
|
Cash and investments |
$ |
71,978 |
$ |
82,270 | |
|
Accounts receivable |
11,421 | 5,245 | |||
|
Inventory |
15,634 | 10,955 | |||
|
Prepaid and other current assets |
9,978 | 12,071 | |||
|
Property and equipment |
14,560 | 8,548 | |||
|
Long-term restricted cash |
4,500 | 4,500 | |||
|
Other long-term Assets |
9,813 | 7,518 | |||
|
Total Assets |
$ |
137,884 |
$ |
131,107 | |
|
Liabilities and Stockholders' Equity |
|||||
|
Accounts payable |
$ |
8,359 |
$ |
4,749 | |
|
Accrued expenses |
16,604 | 15,551 | |||
|
Deferred service revenue |
8,427 | 7,958 | |||
|
Deferred contractual revenue |
— |
12,134 | |||
|
Other liabilities |
3,364 | 1,627 | |||
|
Financing derivative |
356 | 600 | |||
|
Notes payable |
16,106 | 14,948 | |||
|
Stockholders' equity |
84,668 | 73,540 | |||
|
Total Liabilities and Stockholders' Equity |
$ |
137,884 |
$ |
131,107 | |
|
|
|||||